Post-Marketing Safety Concerns with Esketamine: A Disproportionality Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System
Gastaldon, C., Raschi, E., Kane, J. M., Barbui, C., & Schoretsanitis, G. | Psychotherapy and psychosomatics | December 2020
Neurocognitive impact of ketamine treatment in major depressive disorder: A review on human and animal studies – PubMed
Crisanti, C., Enrico, P., Fiorentini, A., Delvecchio, G., & Brambilla, P. | Journal of Affective Disorders | 1 November 2020
Compassionate use of psychedelics
Greif, A., & Šurkala, M. | Medicine, Health Care, and Philosophy | 23 September 2020
The psychoactive aminoalkylbenzofuran derivatives, 5-APB and 6-APB, mimic the effects of 3,4-methylenedioxyamphetamine (MDA) on monoamine transmission in male rats
Brandt, S. D., Walters, H. M., Partilla, J. S., Blough, B. E., Kavanagh, P. V., & Baumann, M. H. | Psychopharmacology | 01 September 2020
Phytochemical, Cytotoxicity, Antioxidant and Anti-Inflammatory Effects of Psilocybe Natalensis Magic Mushroom
Nkadimeng, S. M., Nabatanzi, A., Steinmann, C. M., & Eloff, J. N. | Plants | 31 August 2020
Are Psychedelics Something New in Teaching Psychopharmacology?
Louie, A. K., Beresin, E. V., Coverdale, J., Balon, R., Guerrero, A. P., Morreale, M. K., & Brenner, A. M. | Academic Psychiatry | 28 August 2020